Biomarkers and Early Detection Strategies of Ovarian Cancer

Dear Colleagues,

Ovarian cancer (OC) is the deadliest of all gynecologic malignancies. The 5-year relative survival rate is 92.4% if the disease is diagnosed at the localized (early) stage; however, this decreases to 31.5% when diagnosed at the distant (late) stage. Approximately 70% of patients with OC are diagnosed at advanced stages, which are associated with poor prognosis and low survival rate.

Early detection is critical to achieve a high cure rate for OC patients. Biomarkers have been rapidly emerging for OC, e.g., CA125, HE4, miR-126, and miR-200a. However, an effective strategy for OC early detection is not available currently. Low specificity and high false-positive rates represent limitations of screening programs. Ongoing studies are attempting to identify effective specific biomarkers and screening strategies requiring a single biomarker or a combination of multiple biological measures.

The manuscripts that will be considered for this Special Issue include original research articles and reviews. Studies conducted using cell/tissue culture systems, vertebrate animal models, or human subjects are welcome. The goal is to increase our knowledge of molecular mechanisms, cellular events, and pathological parameters in OC development and metastases. Findings will provide valuable insights into OC pathology, facilitating diagnosis and treatment and the development of early-detection strategies.

Dr. Fuhua Xu
Dr. Tanja Pejovic
Dr. Jing Xu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Genes is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• ovarian cancer
• biomarker
• early detection